×

Biotech and Pharmaceuticals Pharmaceuticals

  • Patients on Vivus' late-stage developmental diet drug, Qnexa, lost an average 37 pounds in 13 months.

  • Amgen

    Amgen reported quarterly results that outpaced what Wall Street was expecting, and the company boosted its outlook for its full-year profit. But the company's shares declined in extended trading.

  • Eli_Lilly_200.jpg

    The folks at Eli Lilly probably cringe every time I go here, but the company this morning reported that third quarter U.S. sales of the erectile dysfunction drug Cialis sprung 13 percent to nearly $159 million.

  • earnings_central_badge.jpg

    One of the things we learned in Pfizer's earnings press release and on the conference call today is that since the start of 2008 the company has eliminated 11,200 positions. And now that the world's biggest pharmaceutical firm has gotten even bigger by swallowing Wyeth, it's going to let go even more people to help wring out about $4 billion in annual expenses by 2012.

  • Pfizer's acquisition of Wyeth will add to the pharmaceutical giant's diversity, which over time will help boost the company's stock, CEO Jeff Kindler told CNBC Tuesday.

  • Amgen

    In case you weren't aware, tomorrow is "World Osteoporosis Day" or WOD, for short, as the International Osteoporosis Foundation hilariously refers to it, but biotech Amgen won't be celebrating the occasion.

  • Stocks pared some of their earlier losses but were still lower as disappointing results from Bank of America and General Electric eclipsed strong results from big techs.

  • Stocks pared some of their earlier losses but were still lower as disappointing results from Bank of America and General Electric eclipsed strong results from big techs.

  • Stocks skidded at the open Friday as disappointing results from Bank of America and General Electric eclipsed strong results from big techs. They slid further — with the Dow down 100 points — after a report showed a surprise drop in consumer sentiment.

  • Futures indicated a lower open for Wall Street Friday, as mixed earnings from General Electric eclipsed strong results from big techs.

  • MM_promo_Cramerica_Challenge_530x50.jpg

    Meaning: shareholders. Here are two companies that delivered surprise quarters – but not in a good way.

  • The Dow pulled off a nearly 50-point  gain Thursday after a topsy-turvy session as the boost from oil's rally ultimately beat out disappointment in earnings from Goldman Sachs and Citigroup.

  • Notes from the front lines of the battle against H1N1. So, I've spent part of yesterday and most of today at the University of Kansas Hospital covering the first H1N1 flu shots being administered.

  • Traders applied the brakes Thursday, a day after the Dow topped 10,000, as Goldman Sachs and Citigroup proved no match for Wall Street's inflated earnings expectations.

  • Stocks pared their losses Thursday after a third straight positive Philly Fed reading — the first time that's happened in two years.  Stocks had opened lower after disappointment in earnings from Goldman Sachs and Citigroup.

  • After Wednesday's stellar market performance, stock index futures indicated a lower open for Wall Street on Thursday as investors take a breather and evaluate their next move.

  • dow_10K_cnbc2_200.jpg

    Stocks rallied Wednesday and the Dow broke through 10,000 for the first time in over a year, fueled by strong earnings from JPMorgan and Intel.

  • swine_flu_needle_200.jpg

    This Friday the CDC is expected to start giving weekly updates on where and how much H1N1 vaccine has been shipped. I'm curious what the demand will truly turn out to be. Some people are growing concerned about the increasing number of pediatric deaths from H1N1 and may rush to get their kids and themselves vaccinated. Others are afraid of or paranoid about the vaccine.

  • Stocks rallied Wednesday, with the Dow homing in on 10,000, after JPMorgan and Intel got earnings season back on track and retail sales fell less than expected.

  • Futures pointed to a strong open Wednesday, with the Dow ready to make another run at 10,000, after JPMorgan and Intel got earnings season back on track and retail sales fell less than expected.